Frost & Sullivan’s Post

Interesting Article… "𝐊𝐞𝐲 𝐓𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 𝐏𝐚𝐫𝐞𝐧𝐭𝐞𝐫𝐚𝐥 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 & 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠" In a discussion hosted by DCAT Value Chain Insights, Claus Feussner (SVP of Development Service at Vetter Pharma) and John Cameron (Director of the Global Injectables Platform at Corden Pharma - A Full-Service CDMO) offered their perspectives on the key trends in parenteral drug development and manufacturing. 👉 Here are the key points: 𝐒𝐡𝐢𝐟𝐭 𝐓𝐨𝐰𝐚𝐫𝐝𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐱 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬: There's a notable move towards developing complex and large-molecule biologics, particularly for targeting specific cancer indications via immunotherapy. 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐂𝐨𝐧𝐯𝐞𝐧𝐢𝐞𝐧𝐜𝐞: There's an ongoing transition towards improving patient convenience through self-administration, leading to the development of patient-friendly delivery systems for at-home administration. 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧: Digitalisation, including artificial intelligence, machine learning, and robotics, is streamlining production processes, enhancing efficiency, and providing insights into unique development processes. 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 (𝐄𝐔 𝐆𝐌𝐏 𝐀𝐧𝐧𝐞𝐱 𝟏): The revised Annex 1 emphasises contamination-control strategy and compliance-management systems to enhance the overall quality and safety of sterile drug products. In summary, the parenteral drug development and manufacturing landscape is evolving rapidly, driven by scientific advancements, patient needs, and regulatory changes. These trends shape the future of healthcare delivery and therapeutic options for patients worldwide. 🔬🚀 #cdmo #pharma #biopharma #biotech

FDA Approvals 2023: Essential Reading for Pharmaceutical Sector Professionals. This article offers key insights and trends, showcasing the direction of the industry. A must-read for those interested in drug development and healthcare innovation.

Biosimilars & Follow-On-Biologics Market Analysis, Trends, Development and Growth Opportunities by Forecast 2033 https://lnkd.in/dYBnKEiM The Biosimilars and Follow-On Biologics Market is a rapidly growing sector within the pharmaceutical industry, driven by the increasing demand for cost-effective treatment options and the expiration of patents for many biologic drugs. Biosimilars are biologic products that are highly similar to an already approved reference biologic (originator biologic), with no clinically meaningful differences in terms of safety, purity, and efficacy. Key Factors Driving the Biosimilars and Follow-On Biologics Market: Cost Savings and Access to Treatment: Biosimilars offer significant cost savings compared to their reference biologics, making them more accessible to patients and healthcare systems. This affordability factor is particularly crucial in managing chronic diseases and expanding treatment options in both developed and emerging markets. Patent Expiry of Biologic Drugs: The expiry of patents for many blockbuster biologic drugs has opened up opportunities for biosimilar manufacturers to enter the market with lower-cost alternatives. This has intensified competition among pharmaceutical companies and increased the availability of biosimilars across therapeutic areas. Regulatory Support and Pathway: Regulatory agencies worldwide, such as the FDA in the United States and the EMA in Europe, have established robust frameworks and pathways for the approval of biosimilars. These regulatory pathways require biosimilar developers to demonstrate similarity to the reference biologic through comprehensive comparability studies, including analytical, non-clinical, and clinical studies. Increasing Acceptance and Physician Confidence: Over time, healthcare providers and physicians have gained confidence in prescribing biosimilars due to the rigorous regulatory approval process and accumulated real-world evidence demonstrating comparable efficacy and safety profiles to reference biologics. This growing acceptance has contributed to the uptake of biosimilars in clinical practice. Disease Management and Therapeutic Innovation: Biosimilars offer opportunities for therapeutic innovation and disease management by expanding treatment options, enhancing patient access to biologic therapies, and driving competition that may lead to improved patient outcomes and healthcare delivery. Market Dynamics and Segmentation: Therapeutic Area: Oncology: Biosimilars for cancer therapies, including monoclonal antibodies such as trastuzumab (Herceptin), rituximab (Rituxan), and bevacizumab (Avastin). Autoimmune Diseases: Biosimilars targeting autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Product Type: Monoclonal Antibodies: Biosimilar versions of monoclonal antibodies, which are co

Thoughts on this? >> Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #healthcare #competitivemarketing

Health-system #pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by sharing new and anticipated novel #drug approvals ASHP

📢 Attention Pharma Enthusiasts! 🌟 Great news! Episode 2 of Pharma Delta's blog series is now live! 💊✨ Discover the latest buzz and insights shaping the pharmaceutical industry. Dive into cutting-edge innovations, strategic collaborations, and more. Don't miss out on staying informed! Read Episode 2 here: https://lnkd.in/dzu33R6N Stay ahead with Pharma Delta. Let's explore the future of healthcare together! 💡🌐 #PharmaDelta #pharmaceutical #pharmaindustry

Biosimilars & Follow-On-Biologics Market Analysis, Trends, Development and Growth Opportunities by Forecast 2033 https://lnkd.in/dYBnKEiM The Biosimilars and Follow-On Biologics Market is a rapidly growing sector within the pharmaceutical industry, driven by the increasing demand for cost-effective treatment options and the expiration of patents for many biologic drugs. Biosimilars are biologic products that are highly similar to an already approved reference biologic (originator biologic), with no clinically meaningful differences in terms of safety, purity, and efficacy. Key Factors Driving the Biosimilars and Follow-On Biologics Market: Cost Savings and Access to Treatment: Biosimilars offer significant cost savings compared to their reference biologics, making them more accessible to patients and healthcare systems. This affordability factor is particularly crucial in managing chronic diseases and expanding treatment options in both developed and emerging markets. Patent Expiry of Biologic Drugs: The expiry of patents for many blockbuster biologic drugs has opened up opportunities for biosimilar manufacturers to enter the market with lower-cost alternatives. This has intensified competition among pharmaceutical companies and increased the availability of biosimilars across therapeutic areas. Regulatory Support and Pathway: Regulatory agencies worldwide, such as the FDA in the United States and the EMA in Europe, have established robust frameworks and pathways for the approval of biosimilars. These regulatory pathways require biosimilar developers to demonstrate similarity to the reference biologic through comprehensive comparability studies, including analytical, non-clinical, and clinical studies. Increasing Acceptance and Physician Confidence: Over time, healthcare providers and physicians have gained confidence in prescribing biosimilars due to the rigorous regulatory approval process and accumulated real-world evidence demonstrating comparable efficacy and safety profiles to reference biologics. This growing acceptance has contributed to the uptake of biosimilars in clinical practice. Disease Management and Therapeutic Innovation: Biosimilars offer opportunities for therapeutic innovation and disease management by expanding treatment options, enhancing patient access to biologic therapies, and driving competition that may lead to improved patient outcomes and healthcare delivery. Market Dynamics and Segmentation: Therapeutic Area: Oncology: Biosimilars for cancer therapies, including monoclonal antibodies such as trastuzumab (Herceptin), rituximab (Rituxan), and bevacizumab (Avastin). Autoimmune Diseases: Biosimilars targeting autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Product Type: Monoclonal Antibodies: Biosimilar versions of monoclonal antibodies, which are co

Promising Developments in IBD Treatment: Analyst Take on Lilly's Acquisition of Morphic ($3.2B) #pharmaceuticals #IBD #drugdevelopment #mergersandacquisitions Excited to share recent news in the pharmaceutical industry! Eli Lilly has acquired Morphic Pharmaceuticals for $3.2 billion. Morphic's lead drug, MORF-057, is an oral treatment for IBD, potentially improving patient experience over current intravenous options like Takeda's Entyvio. Analysts see this as a win for Morphic, with Lilly shouldering the cost of late-stage trials. Could oral IBD treatments be the future? What are your thoughts?

Johnson & Johnson's recent success in the phase 3 trial of their autoimmune drug, nipocalimab, is a significant milestone for the company. The $6.5 billion acquisition of Momenta Pharmaceuticals has proven to be a strategic move, positioning J&J to potentially compete in the treatment of generalized myasthenia gravis (gMG). However, the competitiveness of the late-to-market asset still remains unknown, despite the promising results from the trial. 🌐💉💼 The acquisition of Momenta Pharmaceuticals has opened up a world of opportunities for J&J, providing them with a viable competitor to currently approved drugs from argenx and UCB. With the potential to pursue various indications that could respond well to FcRn blockade, the company stands to gain a significant share of the market. While argenx's setbacks have tempered initial excitement surrounding FcRn, there is still the potential for billions of dollars to be up for grabs in this space. 💰📈💊 In their most recent announcement, J&J shared positive results from the phase 3 clinical trial of nipocalimab in gMG, with the drug meeting its primary endpoint. The successful comparison of nipocalimab and placebo on MG-ADL indicates a positive impact on the daily lives of patients. This exciting development paves the way for discussions with regulators about approving the anti-FcRn antibody for the treatment of gMG. 🎉🔬👩⚕️ #Pharmaceuticals #AutoimmuneTreatment #MedicalInnovation

Thoughts on this? >> Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #biotech #pharmaceutical